<<<Ideas For Now Summer Trading Portfolio >>>
SNY: Sanofi 3.7% yield. Bought at $44--- hasn't gone far. $47.80 I NEED THESE GUYS TO WAKE UP!
GNRC: Generec Bought under $100. Looks good.-> $114 now $122!!
AAWW: Atlas air (Cargo) SOLD!!!! 1st sell of the portfolio!!!<---- SOLD!
LJPC: La Jolla- Septic Shock- This stock appears to have suddenly on Wed left $7 and gone to $5 in a flash. I have no idea why. One reader here was correct this is not working out for me.
Did I miss a downgrade? I have questions in.
A) Amivas, an entity not affiliated with La Jolla, was granted FDA approval of its IV artesunate product.
Artesunate is the active ingredient used in LJPC-0118. Amivas had previously been granted Orphan Drug designation for its IV artesunate product. According to FDA regulations, the FDA will not approve another sponsor's marketing application for the same drug for the same use or indication within 7 years of the initial approval.
Ok that's bad news for sure but Severe Malaria? How much of that is happening...Small market low price per pill... Africa, this is not the drug they are currently using in Covid stuff.. that's
Vials of GIAPREZA shipped from distributors to hospitals grew 58% for the three months ended March 31, 2020... I was betting on Giapreza and got side wiped by a different company different drug that effects a pipeline drug for La Jolla... in a rare sort of disease... Tough decision coming here...
BCRX: Biocryst- anti viral for Covid-- hasn't moved much yet expecting news soon.
Update: These Mfers dropped a secondary for no reason. At first I'm big time mad but now that they have gotten away with it ,maybe it's good they did not have to do this! I'm so pissed I checked their cash and it's over 100 mln these bastards... why!!!! Why.? Hummmm.
That they could do it is good... Now they REALLY have enough cash jesus and they are onto something and they have given these new investors something good in the future without that cliff of an secondary out there.. I'm talking myself into this but Now I see it as good.
(
NASDAQ:BCRX)is planning to sell $100 million of stock in a secondary offering. The underwriters will have a 30-day option to purchase another $15 million, so the
biotechcould potentially gross $115 million in the offering.
BioCryst ended the first quarter with $115 million in the bank, having burned through $23 million during the first quarter, so the capital raise shouldn't come as much of a surprise, although it could have waited until later in the year to do it.
Of course, with shares up 142% since BioCryst announced last month that it was
testingits antiviral medication galidesivir in patients with COVID-19, now seems like as good a time as any to grab some additional cash.
Not just a Covid story...
BioCryst plans to use the capital for pre-launch and commercial activities for berotralstat. The Food and Drug Administration is supposed to make a decision about the marketing application on or before Dec. 3. And a decision in the EU is expected in the first half of next year.
The company also plans to use some of the capital to develop BCX9930 for complement-mediated diseases and for post-approval studies for its flu medication Rapivab that regulators are making the company run.
BioCryst was trading down 4% in after hours trading on the news of the secondary offering that will dilute shareholders by about 13%. The price of the shares being sold in the secondary offering hasn't been set yet.
WPC: REIT-6.3% yield. Price: $63// I'm afraid to look where it is.
We have weathered the stom. Sees stable now
W. P. Carey received 95% of contractual base rent that was due in April, a great achievement compared to many other REITs.
One of the key strengths is the company's well-diversified portfolio, with underweight exposure to retail.
W. P. Carey had some categories that delivered abysmal results, namely 1) Fitness, movie theaters and restaurants and 2) lodging. The good news is that each of these two categories represents just 2% of annual base rent.
Overall, it feels like 'business as usual' for W. P. Carey, at least in terms of rent collection. Not only that, the company recently raised its quarterly cash dividend. Now 6.54%.
POWI: Tech play. Purchase $98--- $111now<---SOLD
CHDN Churchill Downs $127 entry-Gambling play
SE Sea Limited-$78.00 I had entry prices I wanted lower but my stocks have been running away from me as of late...
Alright Up & Down sort of day.... I feel like we are 1 stock or 2 away from smoothing out this portfolio... something like Itron ITRI... Something slightly industrial and value.... Van??????? Where are my ideas!!!! OSIS....
